Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.13	Sanofi Discontinues JAK2 Agent Fedratinib Clinical Trials - Quick Facts (RTTNews)
07.11.13	Sanofi Prices EUR 1 Bln Notes Due 2023 (RTTNews)
30.10.13	Sanofi Q3 Profit Down; Sees Annual EPS At Lower End Of Previous View (RTTNews)
30.10.13	Sanofi Q3 Profit Drops - Quick Facts (RTTNews)
22.10.13	Critical Alerts For Linn Energy, Texas Instruments, Clovis, Sanofi-Aventis, and Cliffs Natural Resources Released By InvestorsObserver (PR Newswire)
16.10.13	Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
16.10.13	Sanofi, Regeneron Say Alirocumab Significantly Reduces Bad Cholesterol (RTTNews)
15.10.13	Nurses' association issues Open Letter to PM Stephen Harper and Premier Wynne urging both to act on poverty (PR Newswire)
07.10.13	Sanofi CEO Expects Return To Growth In Q4 : Bloomberg (RTTNews)
04.10.13	Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA (PR Newswire)
03.10.13	Genzyme Announces Positive Data From TOPIC Study Of Once-daily, Oral Aubagio (RTTNews)
01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
26.09.13	Sanofi Announces the CE Mark for JuniorSTAR®, a New Half-Unit Insulin Reusable Pen for People with Type 1 Diabetes (PR Newswire)
25.09.13	Sanofi Announces Upcoming Launch of MyStar Extra®, the First Self-Monitoring Blood Glucose Meter With Estimated A1c (PR Newswire)
25.09.13	Drug Recommendations, Presentations, Marketing Authorizations, and Board Appointments - Research Report on Johnson & Johnson, Lilly, Sanofi, GSK, and Pacira (PR Newswire)
24.09.13	March of Dimes and Sanofi Pasteur Launch Sounds of Pertussis® "Grandparents' Corner" to Help Grandparents Better Protect Their Families from Whooping Cough (PR Newswire)
24.09.13	Data Show Sanofi's Lyxumia(R) Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled (PR Newswire)
24.09.13	Sanofi Reports GetGoal-L Sub-analysis Results - Quick Facts (RTTNews)
24.09.13	Sanofi Reports FDA Approval For NexGard Chewables - Quick Facts (RTTNews)
20.09.13	Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival - Research Report on Johnson & Johnson, Lilly, GSK, Kythera, and Sanofi (PR Newswire)
19.09.13	Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine (PR Newswire)
18.09.13	Critical Alerts For Intel, Activision, Sanofi Aventis, AOL, and Las Vegas Sands Released By InvestorsObserver (PR Newswire)
17.09.13	Technical Study: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc. (PR Newswire)
17.09.13	NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results - Research Report on Merck, Bristol-Myers Squibb, Amarin, GlaxoSmithKline, and Sanofi (PR Newswire)
17.09.13	European Commission OKs Genzyme's Multiple Sclerosis Treatment Lemtrada (RTTNews)
16.09.13	Sanofi Re-Introduces Rolaids® in the United States (PR Newswire)
16.09.13	Sanofi Re-introduces Rolaids In U.S. - Quick Facts (RTTNews)
14.09.13	Sanofi Likely To Repurchase 9% Stake Of L'Oreal (RTTNews)
12.09.13	Sanofi To Withdraw Lixisenatide NDA In U.S. - Quick Facts (RTTNews)
10.09.13	FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson & Johnson, Novartis, AstraZeneca, Astex Pharmaceuticals, and Sanofi (PR Newswire)
04.09.13	Sanofi, POZEN Sign Deal For Commercialization Of PA8140/PA32540 Tablets In U.S. (RTTNews)
04.09.13	Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S. (PR Newswire)
02.09.13	Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis (PR Newswire)
30.08.13	Genzyme Gets Marketing Authorization For Aubagio In Europe - Quick Facts (RTTNews)
29.08.13	M&A Activities, Pending NDA Approvals, and Clinical Trial Results - Research Report on Sanofi, GSK, AstraZeneca, Keryx, and Rigel (PR Newswire)
29.08.13	Sanofi Prices EUR 1 Bln 2020 Bond Issue - Quick Facts (RTTNews)
26.08.13	Sanofi Pasteur's Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older (PR Newswire)
26.08.13	Sanofi: Fluzone High-Dose Influenza Vaccine Efficacy Trial Meets Primary Goal (RTTNews)
26.08.13	Sanofi Pasteur Reports Topline Results Of Efficacy Trial Of Fluzone High-Dose (RTTNews)
20.08.13	Sanofi Survey Finds Travel Puts Those with Severe Allergies on High Alert (PR Newswire)
19.08.13	Drug Approvals, Clinical Trials, Awards, Offerings, and Earnings - Research Report on J&J, Sanofi, Novartis, BioScrip, and Pacira (PR Newswire)
14.08.13	Licenses, Phase III Trial Initiation and Results, and Investments - Research Report on Johnson & Johnson, Sanofi, AstraZeneca, Novartis, and GSK (PR Newswire)
09.08.13	Technical Scrutiny: Vivus Inc., Sanofi, DENTSPLY Intl., and Acura Pharma (PR Newswire)
06.08.13	HNSN Jumps 22%, MDCO Reaches FINISH Line, SNY's Shot At Superbug Vaccine (RTTNews)
05.08.13	Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium difficile Vaccine in the United States (PR Newswire)
05.08.13	Sanofi Begins Late-stage Study Of Investigational Clostridium Difficile Vaccine (RTTNews)
01.08.13	Sanofi Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff (PR Newswire)
01.08.13	Sanofi Q2 Profit Plunges On Charges, Generics; Cuts View (RTTNews)
01.08.13	Sanofi Q2 Profit Dips - Quick Facts (RTTNews)
31.07.13	Sanofi's Nasacort AQ Nasal Spray Gets FDA Panel Backing (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer
17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung

20.12.24

Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert

04.07.24

Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht

03.07.24

Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	79.18	1.64 %	K V
CieFinRichemont	140.20	1.26 %	K V
Swiss Re	132.30	0.92 %	K V
Swiss Life Hldg	707.40	0.91 %	K V
Zurich Insur Gr	529.40	0.80 %	K V
Roche Hldg G	263.40	-0.57 %	K V
Kuehne+Nagel Int	200.00	-0.65 %	K V
Novartis	90.11	-0.75 %	K V
Givaudan	3’848.00	-0.95 %	K V
Lonza Grp	537.40	-1.29 %	K V

Nachrichten zu Sanofi S.A. (spons. ADRs)

Aktien Top/Flop

Sanofi Peer Group Nachrichten

Meistgelesene Nachrichten